Q2 2024 EPS Estimates for Aspira Women’s Health Inc. (NASDAQ:AWH) Lowered by Analyst

Aspira Women’s Health Inc. (NASDAQ:AWH) – Research analysts at William Blair lowered their Q2 2024 earnings per share estimates for shares of Aspira Women’s Health in a research report issued to clients and investors on Wednesday, May 15th. William Blair analyst A. Brackmann now expects that the company will post earnings per share of ($0.32) for the quarter, down from their prior estimate of ($0.31). The consensus estimate for Aspira Women’s Health’s current full-year earnings is ($1.30) per share. William Blair also issued estimates for Aspira Women’s Health’s Q3 2024 earnings at ($0.28) EPS, Q4 2024 earnings at ($0.28) EPS, FY2024 earnings at ($1.24) EPS, Q1 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.85) EPS.

A number of other equities analysts also recently issued reports on the company. Cantor Fitzgerald reissued a “neutral” rating and set a $3.30 target price on shares of Aspira Women’s Health in a research note on Wednesday, April 10th. StockNews.com assumed coverage on Aspira Women’s Health in a research report on Tuesday. They issued a “hold” rating for the company.

Aspira Women’s Health Trading Up 7.9 %

Shares of AWH stock opened at $2.74 on Monday. The company has a market cap of $34.11 million, a price-to-earnings ratio of -1.89 and a beta of 1.57. The stock has a 50 day simple moving average of $3.20 and a 200-day simple moving average of $3.73. Aspira Women’s Health has a 12-month low of $2.17 and a 12-month high of $6.75.

Aspira Women’s Health (NASDAQ:AWH) last issued its earnings results on Tuesday, May 21st. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). The business had revenue of $2.15 million for the quarter, compared to analysts’ expectations of $2.10 million. Aspira Women’s Health had a negative return on equity of 1,099.32% and a negative net margin of 163.95%. During the same period last year, the company posted ($10.94) earnings per share.

Institutional Trading of Aspira Women’s Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Northeast Financial Consultants Inc purchased a new stake in Aspira Women’s Health during the 3rd quarter worth about $126,000. Quantum Private Wealth LLC boosted its stake in Aspira Women’s Health by 76.8% in the 4th quarter. Quantum Private Wealth LLC now owns 50,156 shares of the company’s stock worth $205,000 after buying an additional 21,788 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. boosted its stake in Aspira Women’s Health by 39.0% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 125,374 shares of the company’s stock worth $672,000 after buying an additional 35,177 shares during the last quarter. Hedge funds and other institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering.